Positive Survival Outcomes from New Phase III Trial in Biliary Tract Cancer Unveiled at ESMO 2026

New Insights into Biliary Tract Cancer Treatment

At the recent European Society for Medical Oncology (ESMO) Congress 2026, groundbreaking results from the Phase III HARMONi-GI1 trial were presented, pointing to a transformational advancement in the treatment of advanced biliary tract cancer (BTC). Akeso, Inc. (HKEX: 9926.HK) introduced its first-in-class drug, ivonescimab, showcasing its potential to significantly improve overall survival when combined with chemotherapy compared to the existing standard treatment, durvalumab.

Study Overview

The HARMONi-GI1 trial was a randomized, controlled, and double-blind study involving multiple centers. It sought to directly compare ivonescimab plus chemotherapy against durvalumab combined with chemotherapy as a first-line treatment for patients suffering from advanced BTC. The study was carefully monitored by an Independent Data Monitoring Committee, ensuring industry-best practices in terms of clinical trial execution and safety monitoring.

In a prespecified interim analysis, the results showed that patients receiving the ivonescimab treatment had a remarkable overall survival (OS) benefit compared to those treated with durvalumab. Notably, this trial became a significant part of the ESMO event due to its Late-Breaking Abstract inclusion, further emphasizing the importance of the findings provided by Professor Jian Zhou, the principal investigator.

Key Findings

1. Overall Survival Improvements: The study indicated a median overall survival rate of 14.9 months for the ivonescimab-treated group, compared to 12.1 months for the durvalumab group. This represents a 25% decrease in the risk of death for patients on ivonescimab, proven statistically significant with a p-value of 0.0031.
- The groundbreaking data suggests that ivonescimab does not only meet but exceeds the previously established benchmarks, providing a compelling case for its use in treating BTC.

2. Progression-Free Survival Enhancements: The trial achieved its secondary endpoint of progression-free survival (PFS), with the ivonescimab arm showing a median PFS of 8.4 months, whereas the durvalumab arm noted only 5.8 months.
- This implies a significant delay in disease progression, with a dramatic 39% reduction in risk for patients treated with ivonescimab.

3. Objective Response Rate: Not only did ivonescimab demonstrate better survival rates, but the study also recorded an objective response rate (ORR) of 53.8%, dramatically outpacing durvalumab at 32.5%. This signifies a substantial difference in the effectiveness of tumor response.

4. Robust Safety Profile: Statistical data regarding adverse effects revealed no new safety signals associated with ivonescimab, with manageable side effects aligned closely to those presented by durvalumab. The incidence rates of serious adverse events were comparable, highlighting the drug's favorable safety profile.

The Significance for Patients

The positive results of the HARMONi-GI1 trial signify a monumental leap forward in the treatment of biliary tract cancers, a disease characterized by dismal prognoses. Approximately half of the patients diagnosed with BTC face an advanced stage, at which point median survival often does not exceed a year. Therefore, the introduction of effective treatment options like ivonescimab is critical.

Furthermore, as the first Phase III trial to yield such compelling results within gastrointestinal cancers, this study broadens the horizon for ivonescimab's clinical applicability beyond lung cancer, establishing it as a noteworthy candidate in a range of malignancies.

Future Directions

Moving forward, ivonescimab is anticipated to be positioned as the new standard of care in treating advanced biliary tract cancer, elevating patient outcomes in this traditionally hard-to-treat area. The drug's acceptance will be bolstered through a proposed Priority Review designation by China’s National Medical Products Administration (NMPA).

In conclusion, the outcomes from this trial not only illuminate the potential of ivonescimab but also set the stage for further collaborative research initiatives, particularly with the recent partnership between Summit Therapeutics and ECOG-ACRIN Cancer Research Group. This collaboration aims to explore even more treatment combinations and optimize therapeutic strategies for patients battling this formidable disease.